Aleafia Health Inc (AH.CA) Fundamental Analysis & Valuation
TSX:AH • CA01444Q1046
Current stock price
0.02 CAD
0 (0%)
Last:
This AH.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. AH.CA Profitability Analysis
1.1 Basic Checks
- AH had negative earnings in the past year.
- In the past year AH has reported a negative cash flow from operations.
- In the past 5 years AH always reported negative net income.
- In the past 5 years AH always reported negative operating cash flow.
1.2 Ratios
- AH has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- AH has a Gross Margin of 21.35%. This is comparable to the rest of the industry: AH outperforms 44.19% of its industry peers.
- AH's Gross Margin has declined in the last couple of years.
- The Profit Margin and Operating Margin are not available for AH so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 21.35% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-52.06%
GM growth 5Y-25.49%
2. AH.CA Health Analysis
2.1 Basic Checks
- AH does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for AH has been increased compared to 1 year ago.
- The debt/assets ratio for AH is higher compared to a year ago.
2.2 Solvency
- AH has an Altman-Z score of -12.50. This is a bad value and indicates that AH is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of AH (-12.50) is worse than 86.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -12.5 |
ROIC/WACCN/A
WACC4.33%
2.3 Liquidity
- AH has a Current Ratio of 0.83. This is a bad value and indicates that AH is not financially healthy enough and could expect problems in meeting its short term obligations.
- With a Current ratio value of 0.83, AH is not doing good in the industry: 74.42% of the companies in the same industry are doing better.
- AH has a Quick Ratio of 0.83. This is a bad value and indicates that AH is not financially healthy enough and could expect problems in meeting its short term obligations.
- With a Quick ratio value of 0.22, AH is not doing good in the industry: 86.05% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.83 | ||
| Quick Ratio | 0.22 |
3. AH.CA Growth Analysis
3.1 Past
- AH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 79.40%, which is quite impressive.
- The Revenue has grown by 52.19% in the past year. This is a very strong growth!
- The Revenue has been growing by 61.75% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)79.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-138.84%
Revenue 1Y (TTM)52.19%
Revenue growth 3Y37.87%
Revenue growth 5Y61.75%
Sales Q2Q%33.46%
3.2 Future
- The Earnings Per Share is expected to grow by 18.32% on average over the next years. This is quite good.
- AH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.85% yearly.
EPS Next Y40%
EPS Next 2Y18.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year51.58%
Revenue Next 2Y31.85%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. AH.CA Valuation Analysis
4.1 Price/Earnings Ratio
- AH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AH. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as AH's earnings are expected to grow with 18.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.32%
EPS Next 3YN/A
5. AH.CA Dividend Analysis
5.1 Amount
- AH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AH.CA Fundamentals: All Metrics, Ratios and Statistics
TSX:AH (7/25/2023, 7:00:00 PM)
0.02
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners2.06%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap8.06M
Revenue(TTM)54.88M
Net Income(TTM)-39.08M
Analysts40
Price Target0.15 (650%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-29.41%
Min Revenue beat(2)-38.79%
Max Revenue beat(2)-20.04%
Revenue beat(4)1
Avg Revenue beat(4)2.93%
Min Revenue beat(4)-38.79%
Max Revenue beat(4)92.17%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.15 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.14
BVpS-0.02
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 21.35% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-52.06%
GM growth 5Y-25.49%
F-Score4
Asset Turnover0.92
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 25.19% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.83 | ||
| Quick Ratio | 0.22 | ||
| Altman-Z | -12.5 |
F-Score4
WACC4.33%
ROIC/WACCN/A
Cap/Depr(3y)79.73%
Cap/Depr(5y)248.52%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-138.84%
EPS Next Y40%
EPS Next 2Y18.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)52.19%
Revenue growth 3Y37.87%
Revenue growth 5Y61.75%
Sales Q2Q%33.46%
Revenue Next Year51.58%
Revenue Next 2Y31.85%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y66.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year309.91%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y89.35%
OCF growth 3YN/A
OCF growth 5YN/A
Aleafia Health Inc / AH.CA Fundamental Analysis FAQ
What is the ChartMill fundamental rating of Aleafia Health Inc (AH.CA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to AH.CA.
What is the valuation status for AH stock?
ChartMill assigns a valuation rating of 0 / 10 to Aleafia Health Inc (AH.CA). This can be considered as Overvalued.
How profitable is Aleafia Health Inc (AH.CA) stock?
Aleafia Health Inc (AH.CA) has a profitability rating of 0 / 10.
How financially healthy is Aleafia Health Inc?
The financial health rating of Aleafia Health Inc (AH.CA) is 0 / 10.